$CRBP
Corbus Pharmaceuticals Holdings, Inc.

2023 Q1 Form 10-K Financial Statement

#000095017023006469 Filed on March 07, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $0.00 $0.00 $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.909M $4.554M $18.70M
YoY Change -25.28% 7.54% -8.45%
% of Gross Profit
Research & Development $13.39M $6.243M $16.14M
YoY Change 307.41% 8.31% -55.72%
% of Gross Profit
Depreciation & Amortization $181.9K $184.4K $763.0K
YoY Change -7.08% -11.21% -23.7%
% of Gross Profit
Operating Expenses $17.30M $10.80M $39.84M
YoY Change 103.08% 7.99% -29.95%
Operating Profit -$17.30M -$39.84M
YoY Change 103.08% -28.85%
Interest Expense -$677.3K -$357.8K -$2.463M
YoY Change -6.8% -3.83% 58.74%
% of Operating Profit
Other Income/Expense, Net -$447.8K $275.6K -$2.511M
YoY Change -51.33% 151.28% -124.27%
Pretax Income -$17.74M -$10.88M -$42.35M
YoY Change 88.03% 6.03% -7.22%
Income Tax
% Of Pretax Income
Net Earnings -$17.74M -$10.88M -$42.35M
YoY Change 88.03% 6.03% -7.22%
Net Earnings / Revenue
Basic Earnings Per Share -$4.24 -$10.15
Diluted Earnings Per Share -$4.24 -$2.62 -$10.15
COMMON SHARES
Basic Shares Outstanding 4.171M 125.3M 4.171M
Diluted Shares Outstanding 4.182M 4.171M

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $44.23M $59.20M $59.20M
YoY Change -48.65% -39.38% -39.38%
Cash & Equivalents $7.324M $17.00M $13.20M
Short-Term Investments $36.90M $42.19M $42.19M
Other Short-Term Assets $1.638M $984.1K $984.1K
YoY Change -30.43% -61.52% -61.52%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $45.86M $60.18M $60.18M
YoY Change -48.16% -39.94% -39.94%
LONG-TERM ASSETS
Property, Plant & Equipment $1.432M $1.614M $5.498M
YoY Change -35.22% -32.55% -21.48%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $182.4K $155.3K $632.8K
YoY Change 142.36% 234.91% 20.8%
Total Long-Term Assets $5.780M $6.131M $6.131M
YoY Change -19.71% -18.53% -18.53%
TOTAL ASSETS
Total Short-Term Assets $45.86M $60.18M $60.18M
Total Long-Term Assets $5.780M $6.131M $6.131M
Total Assets $51.65M $66.31M $66.31M
YoY Change -46.02% -38.45% -38.45%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.323M $2.174M $2.174M
YoY Change -50.94% 21.98% 21.98%
Accrued Expenses $6.468M $5.999M $7.280M
YoY Change 17.68% -40.56% -35.17%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $5.009M $2.796M $3.149M
YoY Change -3.27% -9.62% -18.45%
Total Short-Term Liabilities $14.36M $12.64M $12.64M
YoY Change -5.02% -25.68% -25.68%
LONG-TERM LIABILITIES
Long-Term Debt $13.97M $15.98M $15.98M
YoY Change 1.78% 2.23% 2.23%
Other Long-Term Liabilities $2.522M $22.21K $4.698M
YoY Change 11258.73% 0.0% -21.42%
Total Long-Term Liabilities $16.49M $16.01M $20.68M
YoY Change 19.96% 2.22% -4.32%
TOTAL LIABILITIES
Total Short-Term Liabilities $14.36M $12.64M $12.64M
Total Long-Term Liabilities $16.49M $16.01M $20.68M
Total Liabilities $35.19M $33.32M $33.32M
YoY Change 1.93% -13.72% -13.72%
SHAREHOLDERS EQUITY
Retained Earnings -$409.8M -$392.1M
YoY Change 14.1% 12.11%
Common Stock $422.00 $417.00
YoY Change -96.63% -96.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $16.46M $32.99M $32.99M
YoY Change
Total Liabilities & Shareholders Equity $51.65M $66.31M $66.31M
YoY Change -46.02% -38.45% -38.45%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$17.74M -$10.88M -$42.35M
YoY Change 88.03% 6.03% -7.22%
Depreciation, Depletion And Amortization $181.9K $184.4K $763.0K
YoY Change -7.08% -11.21% -23.7%
Cash From Operating Activities -$15.11M -$7.455M -$37.54M
YoY Change 42.39% -23.16% -22.08%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $13.45K
YoY Change -100.0% -100.0% -75.17%
Acquisitions
YoY Change
Other Investing Activities $5.550M $11.78M $30.09M
YoY Change -87.09% -477.17% -141.01%
Cash From Investing Activities $5.550M $11.78M $30.07M
YoY Change -87.08% -470.74% -140.96%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -113.0K 234.3K -533.6K
YoY Change -65.45% -69.49% -100.88%
NET CHANGE
Cash From Operating Activities -15.11M -7.455M -37.54M
Cash From Investing Activities 5.550M 11.78M 30.07M
Cash From Financing Activities -113.0K 234.3K -533.6K
Net Change In Cash -9.678M 4.559M -8.004M
YoY Change -130.23% -137.64% -86.83%
FREE CASH FLOW
Cash From Operating Activities -$15.11M -$7.455M -$37.54M
Capital Expenditures $0.00 $0.00 $13.45K
Free Cash Flow -$15.11M -$7.455M -$37.56M
YoY Change 42.21% -22.73% -22.14%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001595097
CY2021 us-gaap Repayments Of Debt
RepaymentsOfDebt
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
CY2022 us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q4 us-gaap Derivative Liability Statement Of Financial Position Extensible Enumeration
DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration
http://fasb.org/us-gaap/2022#DerivativeLiabilitiesCurrent
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-392080667
CY2021 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-37348
CY2022 dei Entity Registrant Name
EntityRegistrantName
Corbus Pharmaceuticals Holdings, Inc.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-4348039
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
500 River Ridge Drive
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Norwood
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02062
CY2022 dei City Area Code
CityAreaCode
617
CY2022 dei Local Phone Number
LocalPhoneNumber
963-0100
CY2022 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2022 dei Trading Symbol
TradingSymbol
CRBP
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
31475349
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
4171297
CY2022 dei Auditor Firm
AuditorFirmId
274
CY2022 dei Auditor Name
AuditorName
EISNERAMPER LLP
CY2022 dei Auditor Location
AuditorLocation
Philadelphia, Pennsylvania
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17002715
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25006632
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
42194296
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
72640520
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
192475
CY2021Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
192475
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
791616
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2365010
CY2022Q4 us-gaap Assets Current
AssetsCurrent
60181102
CY2021Q4 us-gaap Assets Current
AssetsCurrent
100204637
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
477425
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
477425
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1613815
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2392696
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3884252
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4609110
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
155346
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
46385
CY2022Q4 us-gaap Assets
Assets
66311940
CY2021Q4 us-gaap Assets
Assets
107730253
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
353323
CY2021Q4 us-gaap Notes Payable Current
NotesPayableCurrent
767938
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2173963
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1782277
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5999252
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10093312
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
36868
CY2021Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
133710
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1280863
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1136948
CY2022Q4 us-gaap Other Long Term Debt Current
OtherLongTermDebtCurrent
2795669
CY2021Q4 us-gaap Other Long Term Debt Current
OtherLongTermDebtCurrent
3093344
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12639938
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
17007529
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
15984426
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
15636275
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
22205
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
22205
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4675354
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5956217
CY2022Q4 us-gaap Liabilities
Liabilities
33321923
CY2021Q4 us-gaap Liabilities
Liabilities
38622226
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4171297
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4171297
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4169631
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4169631
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
417
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
416
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
425196359
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
418903820
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-392080667
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-349733764
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-126092
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-62445
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
32990017
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
69108027
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
66311940
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
107730253
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
881705
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16136826
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
36445285
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18698619
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20425444
CY2022 us-gaap Litigation Settlement Expense
LitigationSettlementExpense
5000000
CY2021 us-gaap Litigation Settlement Expense
LitigationSettlementExpense
0
CY2022 us-gaap Operating Expenses
OperatingExpenses
39835445
CY2021 us-gaap Operating Expenses
OperatingExpenses
56870729
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-39835445
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-55989024
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-48773
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
11899992
CY2022 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-2132091
CY2021 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-1830486
CY2022 us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
96842
CY2021 us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
663290
CY2022 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-427436
CY2021 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-384198
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2511458
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
10348598
CY2022 us-gaap Profit Loss
ProfitLoss
-42346903
CY2021 us-gaap Profit Loss
ProfitLoss
-45640426
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-10.15
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-10.15
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-11.15
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-11.15
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4170675
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4170675
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4094935
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4094935
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-42346903
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-45640426
CY2022 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-63647
CY2021 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-62445
CY2022 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-63647
CY2021 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-62445
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-42410550
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-45702871
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
45274925
CY2021 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1820437
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
59110800
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9480373
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
944800
CY2021 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-62445
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-45640426
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
69108027
CY2022 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
CY2022 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1
CY2022 us-gaap Proceeds From Issuance Of Redeemable Preferred Stock
ProceedsFromIssuanceOfRedeemablePreferredStock
100
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5719637
CY2022 us-gaap Debt Instrument Convertible Beneficial Conversion Feature
DebtInstrumentConvertibleBeneficialConversionFeature
573002
CY2022 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-63647
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-42346903
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
32990017
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-42346903
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-45640426
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
5719637
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
9480373
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
762995
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
999817
CY2021 us-gaap Gain Loss On Sales Of Assets And Asset Impairment Charges
GainLossOnSalesOfAssetsAndAssetImpairmentCharges
-606078
CY2022 crbp Net Amortization On Premium Of Investments
NetAmortizationOnPremiumOfInvestments
-124875
CY2021 crbp Net Amortization On Premium Of Investments
NetAmortizationOnPremiumOfInvestments
-698254
CY2021 crbp Stock Consideration In Connection With Pri License Agreement
StockConsiderationInConnectionWithPriLicenseAgreement
250000
CY2022 crbp Gain Loss On Foreign Exchange Rate
GainLossOnForeignExchangeRate
-648520
CY2021 crbp Gain Loss On Foreign Exchange Rate
GainLossOnForeignExchangeRate
-342424
CY2022 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
724858
CY2021 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
639415
CY2022 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
742478
CY2021 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
700613
CY2022 crbp Realized Loss On Investments
RealizedLossOnInvestments
178222
CY2022 us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
96842
CY2021 us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
663290
CY2022 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-21235
CY2021 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-99520
CY2022 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-1573394
CY2021 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-1347851
CY2021 us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
-1618296
CY2022 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
108961
CY2021 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-187652
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-256835
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-5956297
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-4094160
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-11912120
CY2021 crbp Increase In Other Long Term Liabilities
IncreaseInOtherLongTermLiabilities
-22205
CY2022 crbp Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1136948
CY2021 crbp Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1004062
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-37544435
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-48183697
CY2022 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
86341894
CY2021 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
87266596
CY2022 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
116421376
CY2021 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
13880343
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
13449
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
54172
CY2022 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
8100
CY2021 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
23900
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
30074133
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-73416525
CY2022 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
452250
CY2021 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
984375
CY2022 us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
866865
CY2021 us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
926595
CY2022 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
1381729
CY2022 us-gaap Repayments Of Debt
RepaymentsOfDebt
1500729
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-533615
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
62586070
CY2021 us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
1820437
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
60823413
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-8003917
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-60776809
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
25676532
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
86453341
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
17672615
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
25676532
CY2022 us-gaap Interest Paid Net
InterestPaidNet
1969583
CY2021 us-gaap Interest Paid Net
InterestPaidNet
1740878
CY2021 crbp Write Off Of Fully Depreciated Property And Equipment
WriteOffOfFullyDepreciatedPropertyAndEquipment
544752
CY2022 us-gaap Nature Of Operations
NatureOfOperations
<div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">1.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NATURE OF OPERATIONS</span></div></div><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p><p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Business</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">  </span></p><p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corbus Pharmaceuticals Holdings, Inc. (“the Company” or “Corbus”) is a precision oncology company committed to helping people defeat serious illness by bringing innovative scientific approaches to well understood biological pathways. Corbus’ pipeline being developed internally includes CRB-701, a next generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, and CRB-601, an anti-integrin monoclonal antibody which blocks the activation of TGFβ expressed on cancer cells. The Company also has a pipeline of endocannabinoid small molecule drugs and is seeking partners to fund further development. Since its inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff, acquiring operating assets and raising capital. The Company’s business is subject to significant risks and uncertainties and the Company will be dependent on raising substantial additional capital before it becomes profitable, and it may never achieve profitability.</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
CY2022Q4 crbp Cash And Cash Equivalents And Marketable Debt Securities
CashAndCashEquivalentsAndMarketableDebtSecurities
59197000
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">  </span></p><p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The process of preparing financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates and changes in estimates may occur. The most significant estimates are related to stock-based compensation expense, the accrual of research, product development and clinical obligations, the recognition of revenue under the Investment Agreement (see Note 11), the valuation of warrants</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (see Note 9 and Note 16), and the derivative liability associated with the K2 Loan and Security Agreement (see Note 17).</span></p>
CY2022Q4 us-gaap Cash
Cash
3805156
CY2021Q4 us-gaap Cash
Cash
6751593
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
13197559
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
18255039
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17002715
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25006632
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
192475
CY2021Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
192475
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
477425
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
477425
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
669900
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
669900
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17672615
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25676532
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">  </span></p><p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has no significant off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other hedging arrangements. The Company may, from time to time, have cash in banks in excess of Federal Deposit Insurance Corporation insurance limits. However, the Company believes the risk of loss is minimal as these banks are large financial institutions.</span></p>
CY2021Q3 us-gaap Asset Impairment Charges
AssetImpairmentCharges
606000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
42320000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
42194000
CY2022 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-42346903
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-45640426
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4170675
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4094935
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-10.15
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-11.15
CY2022Q4 crbp Available For Sale Other Investments And Debt Securities Amortized Cost Basis
AvailableForSaleOtherInvestmentsAndDebtSecuritiesAmortizedCostBasis
42320000
CY2022Q4 crbp Available For Sale Other Investments And Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleOtherInvestmentsAndDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2022Q4 crbp Available For Sale Other Investments And Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleOtherInvestmentsAndDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
-126000
CY2022Q4 crbp Available For Sale Securities Other Investments And Debt Securities
AvailableForSaleSecuritiesOtherInvestmentsAndDebtSecurities
42194000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
0
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
0
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
42320000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
42194000
CY2021Q4 crbp Available For Sale Other Investments And Debt Securities Amortized Cost Basis
AvailableForSaleOtherInvestmentsAndDebtSecuritiesAmortizedCostBasis
72703000
CY2021Q4 crbp Available For Sale Other Investments And Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleOtherInvestmentsAndDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2021Q4 crbp Available For Sale Other Investments And Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleOtherInvestmentsAndDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
-62000
CY2021Q4 crbp Available For Sale Securities Other Investments And Debt Securities
AvailableForSaleSecuritiesOtherInvestmentsAndDebtSecurities
72641000
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
44859000
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
44848000
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
11092000
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
11041000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
55951000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
55889000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4707038
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4764938
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3093223
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2372242
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1613815
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2392696
CY2022 us-gaap Depreciation
Depreciation
763000
CY2021 us-gaap Depreciation
Depreciation
1000000
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
1240473
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
1240473
CY2022 us-gaap Lease Cost
LeaseCost
1240473
CY2021 us-gaap Lease Cost
LeaseCost
1240473
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y9M18D
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y9M18D
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0800
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0800
CY2022 us-gaap Operating Lease Expense
OperatingLeaseExpense
1652563
CY2021 us-gaap Operating Lease Expense
OperatingLeaseExpense
1185341
CY2022 crbp Subleases Income
SubleasesIncome
220531
CY2021 crbp Subleases Income
SubleasesIncome
55133
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1700005
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1747447
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1794889
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1688145
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
6930486
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
974269
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
5956217
CY2022 crbp Sublease Agreement Description
SubleaseAgreementDescription
Effective August 26, 2021, the Company entered into a sublease agreement with a third party to sublease 12,112 square feet of the 30,023 square feet currently being leased under one of its two existing lease agreements. The sublease commences on October 1, 2021 and ends October 31, 2026.
CY2022 crbp Subleases Income
SubleasesIncome
220531
CY2021 crbp Subleases Income
SubleasesIncome
55133
CY2022Q4 crbp Future Minimum Sublease Rentals Is Sale Leaseback Transactions Next Twelve Months
FutureMinimumSubleaseRentalsIsSaleLeasebackTransactionsNextTwelveMonths
185717
CY2022Q4 crbp Future Minimum Sublease Rentals Sale Leaseback Transactions Due In Year Two
FutureMinimumSubleaseRentalsSaleLeasebackTransactionsDueInYearTwo
278576
CY2022Q4 crbp Future Minimum Sublease Rentals Sale Leaseback Transactions Due In Year Three
FutureMinimumSubleaseRentalsSaleLeasebackTransactionsDueInYearThree
290688
CY2022Q4 crbp Future Minimum Sublease Rentals Sale Leaseback Transactions Due In Year Four
FutureMinimumSubleaseRentalsSaleLeasebackTransactionsDueInYearFour
252333
CY2022Q4 crbp Future Minimum Sublease Rentals Sale Leaseback Transactions1
FutureMinimumSubleaseRentalsSaleLeasebackTransactions1
1007314
CY2022 us-gaap Interest Expense Debt
InterestExpenseDebt
3097000
CY2021 us-gaap Interest Expense Debt
InterestExpenseDebt
2709000
CY2022Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
20000000
CY2021Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
20000000
CY2022Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
2954390
CY2021Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
2262388
CY2022Q4 crbp Accretion Of Debt Discount
AccretionOfDebtDiscount
1734485
CY2021Q4 crbp Accretion Of Debt Discount
AccretionOfDebtDiscount
992007
CY2022Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
18780095
CY2021Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
18729619
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
2795669
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
3093344
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
15984426
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
15636275
CY2022Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
2977268
CY2022Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
18612732
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
21590000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
9376000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
8656000
CY2022Q4 crbp Accrued Clinical Operations And Trials Costs Current
AccruedClinicalOperationsAndTrialsCostsCurrent
2137317
CY2021Q4 crbp Accrued Clinical Operations And Trials Costs Current
AccruedClinicalOperationsAndTrialsCostsCurrent
5435464
CY2022Q4 crbp Accrued Product Development Costs Current
AccruedProductDevelopmentCostsCurrent
247500
CY2021Q4 crbp Accrued Product Development Costs Current
AccruedProductDevelopmentCostsCurrent
203676
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2224951
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2715368
CY2022Q4 crbp Accrued Administrative Costs
AccruedAdministrativeCosts
473376
CY2021Q4 crbp Accrued Administrative Costs
AccruedAdministrativeCosts
1213699
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
916108
CY2021Q4 us-gaap Interest Payable Current
InterestPayableCurrent
525105
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5999252
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10093312
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-42346903
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-45640426
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
53438141
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
50311967
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
7267176
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
5846372
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
9132973
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
8392989
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
8661477
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
9102630
CY2022Q4 crbp Research And Experimental Costs
ResearchAndExperimentalCosts
3925743
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
503124
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
559876
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1202364
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1284347
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
84130998
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
75498181
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
84130998

Files In Submission

Name View Source Status
0000950170-23-006469-index-headers.html Edgar Link pending
0000950170-23-006469-index.html Edgar Link pending
0000950170-23-006469.txt Edgar Link pending
0000950170-23-006469-xbrl.zip Edgar Link pending
crbp-20221231.htm Edgar Link pending
crbp-20221231.xsd Edgar Link pending
crbp-20221231_htm.xml Edgar Link pending
crbp-ex10_29.htm Edgar Link pending
crbp-ex21_1.htm Edgar Link pending
crbp-ex23_1.htm Edgar Link pending
crbp-ex31_1.htm Edgar Link pending
crbp-ex31_2.htm Edgar Link pending
crbp-ex32_1.htm Edgar Link pending
crbp-ex32_2.htm Edgar Link pending
crbp-ex3_1.htm Edgar Link pending
crbp-ex3_2.htm Edgar Link pending
crbp-ex4_10.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img114058509_0.jpg Edgar Link pending
img114058509_1.jpg Edgar Link pending
img114058509_10.jpg Edgar Link pending
img114058509_11.jpg Edgar Link pending
img114058509_2.jpg Edgar Link pending
img114058509_3.jpg Edgar Link pending
img114058509_4.jpg Edgar Link pending
img114058509_5.jpg Edgar Link pending
img114058509_6.jpg Edgar Link pending
img114058509_7.jpg Edgar Link pending
img114058509_8.jpg Edgar Link pending
img114058509_9.jpg Edgar Link pending
img90588597_0.jpg Edgar Link pending
img90588597_1.jpg Edgar Link pending
img90588597_10.jpg Edgar Link pending
img90588597_11.jpg Edgar Link pending
img90588597_12.jpg Edgar Link pending
img90588597_2.jpg Edgar Link pending
img90588597_3.jpg Edgar Link pending
img90588597_4.jpg Edgar Link pending
img90588597_5.jpg Edgar Link pending
img90588597_6.jpg Edgar Link pending
img90588597_7.jpg Edgar Link pending
img90588597_8.jpg Edgar Link pending
img90588597_9.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
crbp-20221231_def.xml Edgar Link unprocessable
crbp-20221231_pre.xml Edgar Link unprocessable
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
crbp-20221231_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
crbp-20221231_cal.xml Edgar Link unprocessable